Active Ownership Capital proposes to the AGM of STADA Arzneimittel AG the complete replacement of the shareholder representatives in the Supervisory Board - Seite 2
(management) teams.
According to AOC's counter motions, it is proposed that instead of Dr.
Gunnar Riemann, a Supervisory Board candidate put forward by STADA,
Hans-Helmut Fabry (born 1956), former Global Commercial Head Novartis
Consumer Health, is being put up for election. Previously the qualified
psychologist and independent business consultant has been working for
Novartis AG with responsibility for Sandoz Germany and as CEO at Hexal AG.
From 1991 to 2004 he held various positions at L'OREAL. In contrast to Dr.
Gunnar Riemann, Hans-Helmut Fabry possesses comprehensive experience in the
generics, branded product and consumer health business. Instead of Dr.
Birgit Kudlek, who was put forward by STADA, Klaus-Joachim Krauth (born
1961), former CFO of Hexal and Athos is being put up for election. The
qualified industrial engineer is a truly experienced manager and possesses
comprehensive experience in the generics business and additional experience
from management positions in various companies in the supply chain of
companies active in the generics business. As former CFO of several
international groups, he possesses a wide range of finance, controlling and
treasury skills.
The four new candidates have been chosen by a renowned executive search
firm in a professional process with participation of those major
shareholders that followed AOC's call for shareholder participation in the
Aktionärsforum in the German Bundesanzeiger and got in contact with the
executive search firm.
The two candidates proposed by STADA, Tina Müller, currently Chief
Marketing Officer at Opel, and Rolf Hoffmann, in his previous position
member of the extended management board of Amgen, bring the necessary
experience and expertise, their candidacy is thus supported by AOC. Going
forward, the necessary continuity in the Supervisory Board of STADA will be
ensured by the three experienced representatives of the employee side.
In this context, Active Ownership Capital made the following statement:
"The complete replacement of the representatives of the shareholders in
STADA's Supervisory Board is an important step to STADA's long-term
positive development. We are convinced that the Supervisory Board in the
composition we propose possesses an ideal combination of independent
managers with operative skills in the pharma and healthcare industry as
well as experts in finance, human resources, governance and marketing."
The previous public demand by AOC to reclassify STADA's registered shares
with restricted transferability to registered shares has been taken up by
the company and put on the agenda of the AGM on August 26, 2016. After AOC